Third Circuit Affirms Summary Judgment for Pfizer in Zoloft MDL

A Third Circuit Court of Appeals panel recently upheld a lower court’s decision to dismiss plaintiffs’ claims at summary judgment in a multi-district litigation involving Zoloft, an anti-depressant manufactured by Pfizer. The MDL involved 315 plaintiffs alleging that Zoloft causes cardiac birth defects when taken during early pregnancy. The decision, which upheld an earlier ruling by the U.S. District Court for the Eastern District of Pennsylvania, has both good and bad aspects for defendants facing pharmaceutical product liability claims. The plaintiffs introduced several expert witnesses…
Continue reading...

Zoloft MDL Excludes on Daubert Grounds Plaintiffs’ Experts’ Opinions on General Causation

October 9, 2014
/
Daubert
/

Jill C. Owens

Last month the Pennsylvania federal judge presiding over the multi-district litigation in which the plaintiffs allege that the prescription anti-depressant Zoloft, taken during pregnancy, causes birth defects, issued another in an series of Daubert rulings on the plaintiffs’ proposed experts as to general causation. Although the defendant conceded the qualifications of the three research scientists whose expert evidence was being tested, the reliability of their general causation opinions was hotly contested and received a full evidentiary hearing. The Zoloft court’s rulings represent an important addition…
Continue reading...

This Week’s Life Science Headlines

January 2, 2014
/
Class Action Design Defect FDA Litigation Medical Device Nutritional Supplements Pharmaceuticals Product Liability Recalls Regulatory Settlements
/

Life Science Matters

Litigation

Regulatory

Product Liability Regulation to Watch in 2014 (subscription required)
Antabloc Manufacturers Get FDA Warning Letter Over IBD Claims

Recalls

Voluntary Field Corrective Action Initiated for Vital Signs Devices’ CO2 Multi Absorber Due to

This Week’s Life Science Headlines

December 13, 2013
/
Design Defect FDA Litigation Medical Device News Pharmaceuticals Product Liability Recalls Regulatory Settlements Verdicts
/

Life Science Matters

Litigation

High Court Denies Bid to Review Neurontin RICO Rulings (subscription required)
Merck Settles Fosamax Jaw-Injury Claims for $28M (subscription required)
Boehringer Fined $1M For Withholding Docs in MDL (subscription required)
Expert Testimony Must be Backed By Science, Pa. Court Rules (subscription required)
High Court Passes on Lupron Labeling Suit (subscription required)
1st Circ. Ends Takeda FCA Suit But Limits Scope of Ruling (subscription required)
Medtronic Escapes Jury’s $18M Surgical Fire Verdict (subscription required)
J&J Keeps Vaginal Mesh Suit Out of

This Week’s Life Science Headlines

December 1, 2013
/
Design Defect FDA Litigation Medical Device News Nutritional Supplements Pharmaceuticals Product Liability Recalls Regulatory Settlements
/

Life Science Matters

Litigation

Stryker Rejuvenate Lawsuits Filed by Nearly 1,000 Hip Patients Nationwide
Novartis Can’t Apply NJ Punitives Cap in 3 Zometa Suits (subscription required)
Pfizer Escapes FCA Suit Over Anti-Fungal Drug Promotions (subscription required)
Gardasil Lawsuit Filed in France Over Side Effects of HPV Vaccine
Judge Backs Jury Finding in J&J Body Powder Cancer Suit (subscription required)
OxyElite Pro Class Action Filed Over False Advertising
First Zoloft Trial in Federal MDL for Birth Defect Lawsuits to Begin Nov. 2014
J&J Takes Innovative,

This Week’s Life Science Headlines

November 22, 2013
/
Class Action Design Defect FDA Litigation Medical Device News Nutritional Supplements Pharmaceuticals Product Liability Recalls Regulatory Settlements Verdicts
/

Life Science Matters

Litigation

Remicade Lawsuit Filed Over Nerve Paralysis, Breathing Problems
GNC Hit with Suit Linking Supplement to Hepatitis (subscription required)
J&J to Pay $2.5B to Settle Hip Implant Litigation (subscription required)
$25M Hydroxycut Settlement Denied in False Ad MDL (subscription required)
J&J Unit Hit with Suit Over Rheumatoid Arthritis Drug (subscription required)
AMS Pelvic Organ Prolapse Mesh Lawsuit Set for Trial in August 2014
8^th Circ. Returns Boston Scientific Mesh Suits to Fed. Court (subscription required)
3^rd Cir. Affirms Plavix

First New York Court Rejects Controversial Drug Developer Liability Rule

Michael D. Shalhoub

In a controversial 2008 decision in Conte v. Wyeth, Inc., 168 Cal. App. 4th 89 (Cal. Ct. App. 2008), a California Court of Appeals held defendant drug developer, Wyeth, Inc., liable for inadequate warnings in connection with the plaintiff’s use of a competitor’s generic version of the gastrointestinal reflux drug Reglan. The court in Conte held “the common law duty to use due care owed by a name-brand prescription drug manufacturer when providing product warnings extends not only to consumers of its own product,…
Continue reading...

First New York Court Rejects Controversial Drug Developer Liability Rule

November 13, 2013
/
Duty to Warn Labeling Litigation Pharmaceutical/Medical Device/Biotechnology Warnings/Instructions
/

Life Science Matters

This Week’s Life Science Headlines

November 7, 2013
/
FDA Medical Device News Pharmaceuticals Recalls Regulatory Settlements Verdicts
/

Life Science Matters

Litigation

Life Science Matters An inside look at the latest legal developments involving medical devices, pharmaceuticals, and more

Third Circuit Affirms Summary Judgment for Pfizer in Zoloft MDL

Zoloft MDL Excludes on Daubert Grounds Plaintiffs’ Experts’ Opinions on General Causation

This Week’s Life Science Headlines

This Week’s Life Science Headlines

This Week’s Life Science Headlines

This Week’s Life Science Headlines

First New York Court Rejects Controversial Drug Developer Liability Rule

First New York Court Rejects Controversial Drug Developer Liability Rule

This Week’s Life Science Headlines

Take-home Exposure Claims May Lead to COVID-19 Litigation October 21, 2020

Safe Assumption About EPA’S Safer Choice Labels October 16, 2020

New York DOH Fines Long-Term Care Facilities for COVID-19-Related Failures Raising Concerns Regarding Limitations of Immunity Statute October 14, 2020

Should a Head-Spinning “Cure” and “Blessing From God” Abort Well-Established FDA Processes? October 8, 2020

State Law Negligence COVID-19-Related Claims Do Not Fall within PREPA’s Preemptive Scope; Do Not Mandate a Federal Forum October 6, 2020